BLUEBLOOD VENTURES LIMITED
CIN: L70102DL2007PLC159680

Date: 13th November, 2026

To,
The Secretary
BSE Limited
27th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.

Subject: Outcome of Board Meeting and Disclosure under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on Friday, 13th November, 2026, which commenced at 10:00 p.m. and concluded at 11:30 p.m. inter alia, considered and transacted the following matters:

1. Approval of Standalone Unaudited Financial Results

The Board of Directors considered and approved the Standalone Unaudited Financial Results of the Company for the half year ended 30th September, 2026, along with the Limited Review Report issued by the Statutory Auditors of the Company, as reviewed and recommended by the Audit Committee.

2. Related Party Transactions – Purchase of Shares of SJM Investments (Delhi) Private Limited

The Board took note of the purchase by the Company of an aggregate of 62,500 equity shares of SJM Investments (Delhi) Private Limited from the following parties at a rate of ₹825/- per share,

Sr. No.	Name of the Seller	No. of Shares
1.	Beta Stock Brokers (Proprietorship of Mr. Suresh Bohra)	6,650
2.	Babsons HUF	21,327
3.	Mrs. Babita Bohra	8,998
4.	Mr. Rohit Bohra	25,525
Total		**62,500**

3. Subsequent Sale of Shares and Execution of Loan Agreement

The Board further took note that the aforesaid 62,500 equity shares of SJM Investments (Delhi) Private Limited were subsequently sold by the Company to **Dr. Bilha Theresa K. J.** for an aggregate consideration of **Rs. 5,33,08,190/- (Rupees Five Crore Thirty-Three Lakh Eight Thousand One Hundred Ninety Only)**, pursuant to the Share Transfer Agreement dated 28th October, 2026.

BlueBlood Ventures Limited New Delhi

Further, the Board took note of the execution of a Loan Agreement dated 28th October, 2026, with Dr. Bilha Theresa K. J. for an amount of **Rs. 4,46,87,500/- (Rupees Four Crore Forty-Six Lakh Eighty-Seven Thousand Five Hundred Only)**.

4. Assignment of Debt

The Board also took note of the assignment of debt aggregating to **Rs. 17,16,00,000/- (Rupees Seventeen Crore Sixteen Lakh Only)** in favour of Dr. Bilha Theresa K. J., pertaining to the following persons:

Sr. No.	Name	Amount (Rs.)
1.	Mr. Anuranjan Jha	10,72,50,000/-
2.	Mr. Pradeep Kumar Jha	4,14,70,000/-
3.	Mr. Amit Kumar Kushwaha	2,28,80,000/-
	TOTAL	**17,16,00,000/-**

The Board took note of the aforesaid transactions and the agreements executed in connection therewith.

The aforesaid transactions have been disclosed pursuant to Regulation 23 and 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with applicable provisions thereof.

The meeting concluded at 11:30 p.m.

This is for your information and records.

Thanking You,

Yours faithfully,
For Blueblood Ventures Limited

Suresh Bohra
Managing Director

BlueBlood Ventures Limited New Delhi

BLUEBLOOD VENTURES LIMITED
CIN: L70102DL2007PLC159680

November 13th, 2026

To
The Secretary
BSE Limited
27th Floor
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai-400001

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

Under compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby declare that M/s KRA & Associates, Chartered Accountants (Firm Registration No. 002352N), Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the Standalone Un-Audited Financial Results of the Company for the Half Yearly ended 30th September 2026.

Kindly take the above on your records please.

Thanking You

Yours Faithfully
For Blueblood Ventures Limited

BlueBlood Ventures Limited New Delhi

Suresh Bohra
(Managing Director)

KRA & ASSOCIATES

Chartered Accountants

Independent Auditor's Review Report on the Half Yearly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

Review Report to
The Board of Directors
Blueblood Ventures Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Blueblood Ventures Limited (the" Company) for the period ended September 30, 2026 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. We have not performed an audit and accordingly, we do not express an audit opinion.

3. **Emphasis of Matter**
   - i. Zero Optional convertible debentures under non-Current investments Rs 756.00 lakhs as at 30, September 2025 (756 number ZOCDS @ Rs 1 lacs each) out of which 509 number of ZOCDs are in DEMAT account and balance 247 number of ZOCDS is wrongly transferred to one party, for which Management is under process to get back in DEMAT account.
   - ii. Pending confirmations / statement of accounts / follow up documents of old debit balances of long-term loans and advances Rs 6188.55 lakhs has been considered good, as the management is hopeful of recovery /adjustment of the same.
   - iii. The company has made application on Sabka Vishwas (Legacy Dispute Resolution) Scheme, (SVLDRS) 2019 for settlement of the service tax matter of Rs. 27.04 lakhs related to financial year 2017-2018. The Company has filed necessary form SVLDR -1 on 15.01.2020 and liability to be discharged accordingly.
   - iv. The above unaudited results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on **Friday, the 13th day of November, 2026.**
   - v. Previous Period / Year ended figures have been regrouped/reclassified wherever necessary to confirm the current Period / Year end presentation.
   - vi. The figures for half year ended March 31, 2026 represents the balance between audited financials in respect of full financials year and those published till the half year ended 30 September 2025 of the respective financial year.

   Our conclusion is not modified in respect of these matters.



Regd. Office: D-59 & 60 Uttam Nagar East, New Delhi-110059, Ph.:91 11 42470091 Email: raman.arora@kra.net.in

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards (AS) and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the listing regulation, read with the Circular, including the manner in which it is to be disclosed ,or that it contains any material misstatement.

For **KRA & Associates**
Chartered Accountants
Firm Registration No.:002352N

KRA & ASSOCIATES * New Delhi * Chartered Accountants

Raman Arora, Partner
M. No. – 531104
UDIN: 26531104CMDTUA5706
Place: Delhi
Date: 13.11.2026

Blueblood Ventures Limited

Regd Add: M-55,3RD Floor, M-Block Market, G.K.II, New Delhi-110048
Tel: 011-41611745, CIN NO: U70102DL2007PLC159680

Statement of Unaudited Standalone Financial Results for the half year ended 30 September 2026

	Amount in Rs.(Lakhs) unless otherwise specifically stated			
	Standalone			
Particulars	**For the Half year ended 30.09.2026**	**For the Half year ended 31.03.2026**	**For the Half year ended 30.09.2025**	**Financial Year Ended 31.03.2026**
	Unaudited	**Audited**	**Unaudited**	**Audited**
Income				
Revenue from operations	50.00	-21.61	100.79	79.18
Other income	-	21.85	9.61	31.46
Total revenue	**50.00**	**0.24**	**110.40**	**110.64**
		-		
Expense		-		
Purchases of stock-in-trade	-	-	-	-
Changes in inventories of finished goods, work in progress and stock in trade	-	2.00	0.84	2.84
Employee benefits expense	2.02	4.12	0.95	5.07
Finance Cost	9.07	0.03	-	0.03
Depreciation and amortisation expense	0.53	0.03	1.37	1.40
Other expenses	26.62	6.78	90.25	97.03
		-		
Total expenses	38.24	12.95	93.42	106.37
Profit / (Loss) before Exceptional Items and Tax	11.76	(12.71)	16.98	4.27
Less : Exceptional Item	(15.00)			
7. Profit / (Loss) before tax	**(3.24)**	**(12.71)**	**16.98**	**4.27**
Less : Tax Expense				
(a) Current tax expense for current year	-	-1.04	-	-1.04
(b) Deferred tax	-0.09	0.03	-	0.03
Profit / (Loss) for the year after Tax	**(3.33)**	**(13.72)**	**16.98**	**3.26**
Paid Up Equity Share Capital (FV of Rs. 10 each)	**300.11**	**300.11**	**300.11**	**300.11**
Earnings per share (of Rs. 10/- each):				
Basic & Diluted EPS (in Rs.)	(0.11)	(0.46)	0.57	0.11

Notes:

1. Company issued debentures on discount of Rs. 1170.54 Lakh in FY 2017-18 till FY 2020-21 company written off discount on Debentures of Rs. 312.13 Lakh. During the Year company has decided not written off discount on debentures of Rs 78.03 Lakhs through Statement of Profit & Loss and remaining amount of Rs. 858.41 Lakhs to be written off in the Year in which debentures shall be redeemed.
2. As per the notification provided by MCA [vide its press release No. 11/11/2009 dated 2nd, January, 2015] companies whose securities are listed or in the process of listing on SME exchanges shall not be required to apply Ind AS.
3. Balances of Debtors, Creditors & Advances are subject to confirmations.
4. The above un-audited results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on Friday, the 13th day of November, 2026. The results have been audited by the Statutory Auditors of the Company and have issued an unqualified report.
5. Previous Period / Year ended figures have been regrouped/reclassified wherever necessary to confirm the current Period / Year end presentation.
6. The figures year ended March 31, 2026 represents the balance between audited financials in respect of full financials year and those published till the half year ended September 2025 of the respective financial year.

For Blueblood Ventures Limited

Blue Blood Ventures Limited New Delhi

Suresh Bohra
Managing Director
DIN: 00093343

Chandrashekhar Singh
Director
DIN:05131693

Date : 13.11.2026
Place : New Delhi

Blueblood Ventures Limited
C.I.N.: L70102DL2007PLC159680
Unaudited Standalone Balance Sheet as at 30 September ,2026

Amount in INR(Lakhs)

Particulars	Note No.	As at 30th September, 2026	As at 31st March, 2026
EQUITY AND LIABILITIES			
Shareholders' funds			
(a) Share capital	2	300.11	300.11
(b) Reserves and surplus	3	-3.58	-0.27
Non Current Liabilities		-	
(a) Long-term borrowings	4	9,400.00	9,400.00
Current liabilities		-	
(a) Short-term borrowings	5	162.47	50.91
(b) Trade payables	6	-	
(i) Total outstanding dues of micro enterprises and small enterprises		-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises		164.89	119.49
(c) Other current liabilities	7	46.12	47.41
(d) Short - term provision	8	1.05	1.05
		10,071.06	**9,918.70**
ASSETS			
Non Current Assets			
(a) Property, Plant and Equipment			
(i) Tangible assets	9	2.44	2.97
(b) Non-current investments	10	1,233.53	1,229.73
(c) Deferred tax assets (net)	10A	1.87	1.95
(d) Long term loans and advances	11	6,640.57	6,346.28
(e) Other non-current assets	12	858.40	858.40
		-	-
Current Assets		-	-
(a) Inventories	13	48.90	48.90
(b) Trade receivable	14	1,239.80	1,398.69
(c) Cash and cash equivalents	15	1.05	10.58
(d) Short-term loans and advances	16	-	-
(e) Other current assets	17	44.51	21.21
		10,071.06	**9,918.70**

For Blueblood Ventures Limited

Date : 13.11.2026
Place : New Delhi

Suresh Bohra
Managing Director
DIN.: 00093343

Chandrashekhar Singh
Director
DIN:05131693

Blueblood Ventures Limited
C.I.N.: L70102DL2007PLC159680

Statement of Profit and Loss for the half year ended 30th September 2026

Amount in INR (Lakhs)

Particulars	Note No.	For the half year ended 30th September, 2026	For the year ended 31st March, 2026
		Rs.	Rs.
Income			
Revenue from operations	18	50.00	79.18
Other income	19	-	31.46
Total revenue		**50.00**	**110.64**
Expenses			
Purchases of stock-in-trade	20	-	-
Changes in inventories of stock-in-trade	21	-	2.84
Employee benefits expense	22	2.02	5.07
Finance costs	23	9.07	0.03
Depreciation and amortisation expense	24	0.53	1.40
Other expenses	25	41.62	97.03
Total expenses		**53.24**	**106.36**
Profit/(Loss) before tax		**-3.24**	**4.27**
Tax expense:			
(a) Current tax expense		-	1.04
(b) Deferred tax		0.09	-0.03
(c) Taxes for Earlier Years		-	-
		0.09	**1.01**
Profit/(Loss) for the period / year		-3.32	3.26
Earnings / (Loss) per share (of Rs. 10/- each):			
Basic & Diluted EPS (Rs.) (H1 not annualised)	26	-0.11	0.11

For Blueblood Ventures Limited

Suresh Bohra
Managing Director
DIN.: 00093343

Chandrashekhar Singh
Director
DIN:05131693

Blueblood Ventures Limited New Delhi

Date: 13.11.2026
Place: New Delhi

Blueblood Ventures Limited
C.I.N.: L70102DL2007PLC159680
Cash Flow Statement for the half year ended 30th September 2026

	Description	For the half year ended 30th September, 2026	For the year ended 31st March, 2026
		Amount in INR (Lakhs)	
		Rs.	Rs.
A.	**CASH FLOW FROM OPERATING ACTIVITIES**		
I.	Net Profit from P & L A/c	(3.32)	3.26
	Adjustment for:		
	Non - cash adjustment to reconcile profit before tax to net cash flows		
	a) Depreciation / Amortisation	0.53	1.40
	b) Finance cost	9.07	0.03
	c) Interest income	-	(21.46)
	d) Discount on issue of debenture	-	-
	e) Dividend income	-	(0.01)
	f) Deferred Tax effect	0.09	(0.03)
	Operating Profit before working capital changes	6.36	(16.81)
II.	**Changes in working capital**		
	a) Decrease / (Increase) in other Current Assets and Trade Receivables	135.59	713.27
	b) (Decrease) / Increase in Inventories	-	2.84
	c) (Decrease) / Increase in Current Liabilities	155.67	(108.50)
	Cash Generated from operations	297.62	590.80
	Income tax paid	-	-
	NET CASH FROM OPERATING ACTIVITIES	297.62	590.80
B.	**CASH FLOW FROM INVESTING ACTIVITIES**		
	a) Interest received	-	21.46
	b) Dividend received	-	0.01
	c) Sale/(Purchase) of Investment	(3.80)	78.65
	d) Sale/(Purchase) of Fixed Assets	-	(0.21)
	e) Long term loan and advances	(294.29)	(689.58)
	NET CASH FROM INVESTING ACTIVITIES	(298.09)	(589.67)
C.	**CASH FLOW FROM FINANCING ACTIVITIES**		
	a) Proceeds from long term borrowings	-	-
	b) Discount on issue of debentures	-	-
	b) Finance cost	(9.07)	(0.03)
	c) Long term loan and advances	-	-
	NET CASH FROM FINANCING ACTIVITIES	(9.07)	(0.03)
	Total (A+B+C)	(9.53)	1.10
	a) Cash and Cash Equivalents at the beginning of the period / year	10.58	9.48
	b) Cash and Cash Equivalents at the end of the period / year	1.05	10.58
	Net increase / (decrease) in cash and cash equivalents (b-a)	(9.53)	1.10
	Cash and cash equivalents consists of:		
	Cash on hand	0.97	10.57
	Balances with Scheduled banks	0.07	0.01
	Total	1.05	10.58

For Blueblood Ventures Limited

Date : 13.11.2026
Place : New Delhi

Suresh Bohra
Managing Director
DIN.: 00093343

Chandrashekhar Singh
Director
DIN:05131693